<DOC>
	<DOCNO>NCT00052468</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether carboplatin paclitaxel combine gemcitabine effective carboplatin paclitaxel alone treat ovarian epithelial fallopian tube cancer . PURPOSE : This randomized phase III trial study carboplatin paclitaxel combine gemcitabine see well work compare paclitaxel carboplatin alone treat patient undergone surgery ovarian epithelial fallopian tube cancer .</brief_summary>
	<brief_title>Carboplatin/Paclitaxel +/-Gemcitabine Treating Patients With Ovarian Epithelial Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient stage I-IV ovarian epithelial fallopian tube cancer treat adjuvant carboplatin paclitaxel without gemcitabine . - Compare response rate , progression-free survival , duration response patient treat regimen . - Compare toxic effect regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , open-label , control , multicenter study . Patients stratify accord FIGO stage ( I-IIA v IIB-IIIC tumor great 10 mm vs IIB-IIIC tumor great 10 mm IV ) , plan interval surgical debulking ( yes v ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive carboplatin IV 30-60 minute paclitaxel IV 3 hour day 1 gemcitabine IV 30-60 minute day 1 8 . - Arm II : Patients receive carboplatin paclitaxel arm I . Treatment arm repeat every 21 day 6 10 course absence disease progression unacceptable toxicity . Some patient undergo interval debulking surgery . Quality life assess baseline , course 3 6 , 3 , 6 , 12 month completion study . Patients follow every 3 month 2 year , every 6 month 5 year , annually thereafter . PROJECTED ACCRUAL : A total 1,716 patient ( 858 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis one following : Ovarian epithelial cancer FIGO stage IA/B G3 , ICIV Fallopian tube cancer Extraovarian papillary serous tumor The follow ineligible : Low malignantpotential ovarian tumor ( borderline tumor ) Nonepithelial ovarian tumor Mixed Mullerian tumor Must definitive surgery within past 6 week No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 6 month Hematopoietic WBC least 3,000/mm^3 OR Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 10 mg/dL Hepatic Bilirubin great 2 time upper limit normal Renal Glomerular filtration rate least 50 mL/min Cardiovascular No congestive heart failure No myocardial infarction within past 6 month No New York Heart Association class III IV heart disease No prior atrial ventricular arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior seizures central nervous system disorder No prior severe hypersensitivity reaction product contain Cremophor EL ( e.g. , cyclosporine vitamin K ) No know hypersensitivity compound chemically related carboplatin , gemcitabine , paclitaxel No preexist motor sensory neuropathy great grade 1 No malignancy within past 5 year except : Malignancies cure surgery alone Carcinoma situ cervix Adequately treat basal cell skin cancer No complete bowel obstruction No concurrent severe medical condition would preclude study participation No dementia significantly alter mental status would preclude study participation No concurrent severe active infection Geographically accessible treatment followup PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy No concurrent hormonal therapy except : Hormone replacement therapy Antiemetic steroid Radiotherapy No prior radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics Recovered prior surgery Other No concurrent antineoplastic agent No concurrent investigational drug No concurrent clinical trial enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
</DOC>